Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201600041C
Awardee
Awarding agency
Obligated
$1,489,000

Award facts

Opportunity
  • BAAN4CO6700679 Solicitation number
Contract value 100% obligated
$1,489,000.12 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Davis, CA, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00003 -$10,999
Change Order 2 $0
Change Order 1 $0
Original award $1,499,999

About this award

This is a cost-plus-fixed-fee SBIR Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to LP Therapeutics, Inc. for the development of novel therapeutic agents targeting cancer stem cells. The contract has a total ceiling value of $1,489,000.12 and a period of performance ending on March 18, 2019. The contract was set aside for small businesses. No information is provided about major subcontractors.

Quick answers

Who was awarded contract HHSN261201600041C?

HHSN261201600041C was awarded to LP Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600041C worth?

The government has obligated $1,489,000 on HHSN261201600041C.

Was contract HHSN261201600041C competed?

The extent of competition for HHSN261201600041C was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award